Cytosorbents SG&A Expenses 2010-2024 | CTSO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cytosorbents sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cytosorbents sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$204.2B
Stryker (SYK)	$146.7B
Boston Scientific (BSX)	$132.6B
EssilorLuxottica (ESLOY)	$112.1B
Medtronic (MDT)	$110.6B
Haleon (HLN)	$43.7B
Lonza Group Ag (LZAGY)	$42.2B
GE HealthCare Technologies (GEHC)	$37.7B
ResMed (RMD)	$35.8B
Terumo (TRUMY)	$29.7B
Koninklijke Philips (PHG)	$24.8B
Zimmer Biomet Holdings (ZBH)	$21.9B
Insulet (PODD)	$18.4B
Baxter (BAX)	$17B
Smith & Nephew SNATS (SNN)	$11.1B
BellRing Brands (BRBR)	$10.2B
Bio-Rad Laboratories (BIO)	$9.3B
Demant (WILYY)	$8.3B
Lantheus Holdings (LNTH)	$6.3B
TG Therapeutics (TGTX)	$5.5B
Haemonetics (HAE)	$4.3B
Prestige Consumer Healthcare (PBH)	$4.2B
ICU Medical (ICUI)	$4.1B
Perrigo (PRGO)	$3.8B
Envista Holdings (NVST)	$3.7B
Neogen (NEOG)	$3.2B
Agios Pharmaceuticals (AGIO)	$3.2B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.8B
QuidelOrtho (QDEL)	$2.7B